X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA WYETH LTD SHASUN PHARMA/
WYETH LTD
 
P/E (TTM) x 123.9 27.7 447.0% View Chart
P/BV x 8.5 5.3 159.5% View Chart
Dividend Yield % 0.2 1.3 18.3%  

Financials

 SHASUN PHARMA   WYETH LTD
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
WYETH LTD
Mar-13
SHASUN PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs941,044 9.0%   
Low Rs46818 5.6%   
Sales per share (Unadj.) Rs214.2298.6 71.7%  
Earnings per share (Unadj.) Rs5.357.2 9.3%  
Cash flow per share (Unadj.) Rs15.858.4 27.1%  
Dividends per share (Unadj.) Rs1.0017.00 5.9%  
Dividend yield (eoy) %1.41.8 78.4%  
Book value per share (Unadj.) Rs53.3249.5 21.4%  
Shares outstanding (eoy) m56.6222.72 249.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.1 10.5%   
Avg P/E ratio x13.116.3 80.5%  
P/CF ratio (eoy) x4.415.9 27.7%  
Price / Book Value ratio x1.33.7 35.1%  
Dividend payout %18.729.7 63.1%   
Avg Mkt Cap Rs m3,95821,157 18.7%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m2,164400 540.9%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m12,1276,783 178.8%  
Other income Rs m229353 65.0%   
Total revenues Rs m12,3567,136 173.2%   
Gross profit Rs m1,0091,617 62.4%  
Depreciation Rs m59427 2,231.6%   
Interest Rs m4156 7,547.3%   
Profit before tax Rs m2301,938 11.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m-73632 -11.5%   
Profit after tax Rs m3021,301 23.2%  
Gross profit margin %8.323.8 34.9%  
Effective tax rate %-31.732.6 -97.0%   
Net profit margin %2.519.2 13.0%  
BALANCE SHEET DATA
Current assets Rs m6,8846,984 98.6%   
Current liabilities Rs m8,4562,056 411.3%   
Net working cap to sales %-13.072.6 -17.8%  
Current ratio x0.83.4 24.0%  
Inventory Days Days6299 62.1%  
Debtors Days Days10824 449.3%  
Net fixed assets Rs m4,970244 2,034.5%   
Share capital Rs m113227 49.9%   
"Free" reserves Rs m2,8755,441 52.8%   
Net worth Rs m3,0205,668 53.3%   
Long term debt Rs m1,81725 7,269.6%   
Total assets Rs m13,3477,901 168.9%  
Interest coverage x1.6353.3 0.4%   
Debt to equity ratio x0.60 13,642.8%  
Sales to assets ratio x0.90.9 105.8%   
Return on assets %5.416.5 32.5%  
Return on equity %10.022.9 43.6%  
Return on capital %13.334.0 39.1%  
Exports to sales %46.40.2 21,246.6%   
Imports to sales %14.236.3 39.2%   
Exports (fob) Rs m5,62215 37,983.1%   
Imports (cif) Rs m1,7282,465 70.1%   
Fx inflow Rs m5,84315 38,438.2%   
Fx outflow Rs m2,1732,677 81.2%   
Net fx Rs m3,669-2,662 -137.8%   
CASH FLOW
From Operations Rs m398923 43.1%  
From Investments Rs m-1,635317 -515.9%  
From Financial Activity Rs m1,309-481 -272.1%  
Net Cashflow Rs m71759 9.4%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 3.6 11.3 31.9%  
FIIs % 17.6 7.2 244.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 30.4 130.3%  
Shareholders   20,750 21,978 94.4%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   ALEMBIC LTD  SUN PHARMA  SANOFI INDIA  FDC LTD.  AUROBINDO PHARMA  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS